670 related articles for article (PubMed ID: 12836729)
1. PDE-5 inhibition and sexual response: pharmacological mechanisms and clinical outcomes.
Rosen RC; McKenna KE
Annu Rev Sex Res; 2002; 13():36-88. PubMed ID: 12836729
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness of sildenafil citrate (Viagra) and tadalafil (Cialis) on sexual responses in Saudi men with erectile dysfunction in routine clinical practice.
Ali ST
Pak J Pharm Sci; 2008 Jul; 21(3):275-81. PubMed ID: 18614424
[TBL] [Abstract][Full Text] [Related]
3. Erectile dysfunction: comparison of efficacy and side effects of the PDE-5 inhibitors sildenafil, vardenafil and tadalafil--review of the literature.
Gresser U; Gleiter CH
Eur J Med Res; 2002 Oct; 7(10):435-46. PubMed ID: 12435622
[TBL] [Abstract][Full Text] [Related]
4. Type 5 phosphodiesterase inhibitors in the treatment of erectile dysfunction and cardiovascular disease.
Ravipati G; McClung JA; Aronow WS; Peterson SJ; Frishman WH
Cardiol Rev; 2007; 15(2):76-86. PubMed ID: 17303994
[TBL] [Abstract][Full Text] [Related]
5. Drug Insight: oral phosphodiesterase type 5 inhibitors for erectile dysfunction.
Briganti A; Salonia A; Gallina A; Saccà A; Montorsi P; Rigatti P; Montorsi F
Nat Clin Pract Urol; 2005 May; 2(5):239-47. PubMed ID: 16474835
[TBL] [Abstract][Full Text] [Related]
6. Erectile function and assessments of erection hardness correlate positively with measures of emotional well-being, sexual satisfaction, and treatment satisfaction in men with erectile dysfunction treated with sildenafil citrate (Viagra).
Montorsi F; Padma-Nathan H; Glina S
Urology; 2006 Sep; 68(3 Suppl):26-37. PubMed ID: 17011373
[TBL] [Abstract][Full Text] [Related]
7. Factors associated with preference for sildenafil citrate and tadalafil for treating erectile dysfunction in men naïve to phosphodiesterase 5 inhibitor therapy: post hoc analysis of data from a multicentre, randomized, open-label, crossover study.
Eardley I; Montorsi F; Jackson G; Mirone V; Chan ML; Loughney K; Vail GM; Beardsworth A
BJU Int; 2007 Jul; 100(1):122-9. PubMed ID: 17552960
[TBL] [Abstract][Full Text] [Related]
8. In vivo and in vitro response of corpus cavernosum to phosphodiesterase-5 inhibition in the hypercholesterolaemic rabbit.
Firoozi F; Longhurst PA; White MD
BJU Int; 2005 Jul; 96(1):164-8. PubMed ID: 15963142
[TBL] [Abstract][Full Text] [Related]
9. [Sex, erectile dysfunction, and the heart: a growing problem].
Görge G; Flüchter S; Kirstein M; Kunz T
Herz; 2003 Jun; 28(4):284-90. PubMed ID: 12825143
[TBL] [Abstract][Full Text] [Related]
10. Do vardenafil and tadalafil have advantages over sildenafil in the treatment of erectile dysfunction?
Doggrell S
Int J Impot Res; 2007; 19(3):281-95. PubMed ID: 17183346
[TBL] [Abstract][Full Text] [Related]
11. Phosphodiesterase type 5 inhibitors in pulmonary arterial hypertension.
Montani D; Chaumais MC; Savale L; Natali D; Price LC; Jaïs X; Humbert M; Simonneau G; Sitbon O
Adv Ther; 2009 Sep; 26(9):813-25. PubMed ID: 19768639
[TBL] [Abstract][Full Text] [Related]
12. Emerging oral drugs for erectile dysfunction.
Briganti A; Salonia A; Gallina A; Suardi N; Rigatti P; Montorsi F
Expert Opin Emerg Drugs; 2004 May; 9(1):179-89. PubMed ID: 15155143
[TBL] [Abstract][Full Text] [Related]
13. Tadalafil (Cialis) for men with erectile dysfunction.
Eardley I; Cartledge J
Int J Clin Pract; 2002 May; 56(4):300-4. PubMed ID: 12074215
[TBL] [Abstract][Full Text] [Related]
14. Sildenafil: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction.
Boolell M; Allen MJ; Ballard SA; Gepi-Attee S; Muirhead GJ; Naylor AM; Osterloh IH; Gingell C
Int J Impot Res; 1996 Jun; 8(2):47-52. PubMed ID: 8858389
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic effectiveness and patient satisfaction after 6 months of treatment with tadalafil, sildenafil, and vardenafil: results from the erectile dysfunction observational study (EDOS).
Martin-Morales A; Haro JM; Beardsworth A; Bertsch J; Kontodimas S;
Eur Urol; 2007 Feb; 51(2):541-50; discussion 550. PubMed ID: 17084518
[TBL] [Abstract][Full Text] [Related]
16. Phosphodiesterase 5 inhibitors for erectile dysfunction.
Setter SM; Iltz JL; Fincham JE; Campbell RK; Baker DE
Ann Pharmacother; 2005; 39(7-8):1286-95. PubMed ID: 15941818
[TBL] [Abstract][Full Text] [Related]
17. Sildenafil citrate for erectile dysfunction in men with diabetes and cardiovascular risk factors: a retrospective analysis of pooled data from placebo-controlled trials.
Blonde L
Curr Med Res Opin; 2006 Nov; 22(11):2111-20. PubMed ID: 17076971
[TBL] [Abstract][Full Text] [Related]
18. Vardenafil improved patient satisfaction with erectile hardness, orgasmic function and sexual experience in men with erectile dysfunction following nerve sparing radical prostatectomy.
Nehra A; Grantmyre J; Nadel A; Thibonnier M; Brock G
J Urol; 2005 Jun; 173(6):2067-71. PubMed ID: 15879836
[TBL] [Abstract][Full Text] [Related]
19. Pharmacology of phosphodiesterase 5 inhibitors.
Carrier S
Can J Urol; 2003 Feb; 10 Suppl 1():12-6. PubMed ID: 12625845
[TBL] [Abstract][Full Text] [Related]
20. Tadalafil and vardenafil vs sildenafil: a review of patient-preference studies.
Mirone V; Fusco F; Rossi A; Sicuteri R; Montorsi F
BJU Int; 2009 May; 103(9):1212-7. PubMed ID: 19154480
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
